RTTNews | Dec 14, 2021 09:03AM EST

09:03 Tuesday, December 14, 2021 (RTTNews.com) - Shares of Atara Biotherapeutics, Inc. (ATRA), are trading 3 percent higher in pre-market on Tuesday after the company engaged in T-cell immunotherapy, announced efficacy and safety results from its study investigating tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease.

Tabelecleucel (tabcel) is an off-the-shelf, allogeneic T-cell immunotherapy in development for the treatment of a type of cancer that may occur after a solid organ transplant (SOT) or allogeneic hematopoietic cell transplant (HCT).

The study revealed one-year survival rate of 89.2 percent for patients responding to Tab-cel Compared with 32.4 percent among non-responders. Safety was consistent with previously published data, and no new safety signals or concerns were reported.

Tab-cel's potential as a first-in-class treatment option for transplant recipients that develop EBV+ PTLD is validated by almost 90 percent of patients responding to treatment surviving after one year, and a similar two-year survival benefit of over 86 percent in patients who achieved a complete or partial response from Phase 2 and EAP studies.

Shares of Atara Biotherapeutics is currently trading in pre-market at $16.13, up $0.47 or 3 percent from previous close.

Read the original article on RTTNews ( https://www.rttnews.com/3249171/atara-biotherapeutics-rises-in-pre-market-on-positive-phase-3-trial-results-of-tab-cel.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved